Evolva Holding SA (EVE.SW)
CHF 0.84
(-6.44%)
CHF 0.84
(-6.44%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -92.24 Million CHF | 102.17% |
| 2022 | -23.35 Million CHF | 26.78% |
| 2021 | -31.9 Million CHF | -49.74% |
| 2020 | -21.3 Million CHF | -5.85% |
| 2019 | -20.12 Million CHF | 34.51% |
| 2018 | -30.73 Million CHF | 31.55% |
| 2017 | -44.89 Million CHF | -9.06% |
| 2016 | -41.16 Million CHF | -15.23% |
| 2015 | -35.72 Million CHF | -56.99% |
| 2014 | -22.75 Million CHF | -28.66% |
| 2013 | -17.68 Million CHF | 11.8% |
| 2012 | -20.05 Million CHF | 22.68% |
| 2011 | -25.93 Million CHF | -12.21% |
| 2010 | -23.11 Million CHF | -160.68% |
| 2009 | -8.86 Million CHF | 87.23% |
| 2008 | -69.42 Million CHF | -15.2% |
| 2007 | -60.26 Million CHF | 18.13% |
| 2006 | -73.61 Million CHF | -101.85% |
| 2005 | -36.47 Million CHF | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 1.31 Million CHF | 0.0% |
| 2023 Q2 | -9.81 Million CHF | 0.0% |
| 2023 Q4 | 78.11 Million CHF | 0.0% |
| 2023 FY | 506.2 Thousand CHF | 102.17% |
| 2022 Q2 | -13.89 Million CHF | 0.0% |
| 2022 Q4 | -9.46 Million CHF | 0.0% |
| 2022 FY | -23.35 Million CHF | 26.78% |
| 2021 FY | -31.9 Million CHF | -49.74% |
| 2021 Q4 | -15.03 Million CHF | 0.0% |
| 2021 Q2 | -17.36 Million CHF | 0.0% |
| 2020 FY | -21.3 Million CHF | -5.85% |
| 2020 Q2 | -12.61 Million CHF | 0.0% |
| 2020 Q4 | -12.29 Million CHF | 0.0% |
| 2019 FY | -20.12 Million CHF | 34.51% |
| 2019 Q2 | -9.57 Million CHF | 0.0% |
| 2019 Q4 | -10.55 Million CHF | 0.0% |
| 2018 FY | -30.73 Million CHF | 31.55% |
| 2018 Q2 | -15.76 Million CHF | 0.0% |
| 2018 Q4 | -14.97 Million CHF | 0.0% |
| 2017 Q2 | -20.68 Million CHF | 0.0% |
| 2017 FY | -44.89 Million CHF | -9.06% |
| 2017 Q4 | -24.21 Million CHF | 0.0% |
| 2016 FY | -41.16 Million CHF | -15.23% |
| 2016 Q2 | -20.56 Million CHF | 0.0% |
| 2016 Q4 | -20.6 Million CHF | 0.0% |
| 2015 FY | -35.72 Million CHF | -56.99% |
| 2015 Q4 | -18.78 Million CHF | 0.0% |
| 2015 Q2 | -16.94 Million CHF | 0.0% |
| 2014 Q4 | -11.91 Million CHF | 0.0% |
| 2014 FY | -22.75 Million CHF | -28.66% |
| 2014 Q2 | -10.84 Million CHF | 0.0% |
| 2013 Q4 | -8.69 Million CHF | 0.0% |
| 2013 FY | -17.68 Million CHF | 11.8% |
| 2013 Q2 | -8.99 Million CHF | 0.0% |
| 2012 FY | -20.05 Million CHF | 22.68% |
| 2012 Q4 | -4.25 Million CHF | -0.54% |
| 2012 Q1 | -4.23 Million CHF | 0.0% |
| 2012 Q2 | -4.23 Million CHF | 0.0% |
| 2012 Q3 | -4.23 Million CHF | 0.0% |
| 2011 Q1 | -5.89 Million CHF | 0.0% |
| 2011 Q2 | -5.89 Million CHF | 0.0% |
| 2011 Q3 | -5.89 Million CHF | 0.0% |
| 2011 Q4 | -4.23 Million CHF | 28.11% |
| 2011 FY | -25.93 Million CHF | -12.21% |
| 2010 FY | -23.11 Million CHF | -160.68% |
| 2010 Q4 | -5.89 Million CHF | -9.53% |
| 2010 Q3 | -5.38 Million CHF | 0.0% |
| 2010 Q2 | -5.38 Million CHF | 0.0% |
| 2010 Q1 | -5.38 Million CHF | 0.0% |
| 2009 Q2 | -2.09 Million CHF | 0.0% |
| 2009 Q4 | -5.38 Million CHF | -156.75% |
| 2009 Q3 | -2.09 Million CHF | 0.0% |
| 2009 FY | -8.86 Million CHF | 87.23% |
| 2009 Q1 | -2.09 Million CHF | 0.0% |
| 2008 Q1 | -16.59 Million CHF | 0.0% |
| 2008 Q4 | -2.09 Million CHF | 87.37% |
| 2008 Q3 | -16.59 Million CHF | 0.0% |
| 2008 FY | -69.42 Million CHF | -15.2% |
| 2008 Q2 | -16.59 Million CHF | 0.0% |
| 2007 Q3 | -14.68 Million CHF | 0.0% |
| 2007 Q1 | -14.68 Million CHF | 0.0% |
| 2007 Q4 | -16.59 Million CHF | -13.05% |
| 2007 FY | -60.26 Million CHF | 18.13% |
| 2007 Q2 | -14.68 Million CHF | 0.0% |
| 2006 Q3 | -18.1 Million CHF | 0.0% |
| 2006 Q2 | -18.1 Million CHF | 0.0% |
| 2006 Q1 | -18.1 Million CHF | 0.0% |
| 2006 FY | -73.61 Million CHF | -101.85% |
| 2006 Q4 | -14.68 Million CHF | 18.92% |
| 2005 FY | -36.47 Million CHF | 0.0% |
| 2005 Q4 | -18.1 Million CHF | -106.76% |
| 2005 Q3 | -8.75 Million CHF | 0.0% |
| 2005 Q2 | -8.75 Million CHF | 0.0% |
| 2005 Q1 | -8.75 Million CHF | 0.0% |
| 2004 Q4 | -8.75 Million CHF | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Addex Therapeutics Ltd | -10.31 Million CHF | -794.614% |
| BB Biotech AG | -29.92 Million CHF | -208.224% |
| Basilea Pharmaceutica AG | 19.2 Million CHF | 580.319% |
| Idorsia Ltd | -543.05 Million CHF | 83.014% |
| Kuros Biosciences AG | -13.19 Million CHF | -599.252% |
| Molecular Partners AG | -61.1 Million CHF | -50.955% |
| Relief Therapeutics Holding AG | -110.82 Million CHF | 16.767% |
| Santhera Pharmaceuticals Holding AG | 68.84 Million CHF | 233.992% |